📊 NATR Key Takeaways
Is NATR a Good Investment? Thesis Analysis
NATR demonstrates strong financial health with minimal debt, substantial cash reserves ($93.9M), and consistent free cash flow generation ($28.8M), but faces profitability headwinds with flat net income growth despite 5.7% revenue growth, indicating margin compression and operational efficiency challenges in a mature pharmaceutical market.
Why Buy NATR? Key Strengths
- Exceptional balance sheet strength with 0.01x debt-to-equity ratio and minimal long-term debt ($2.1M)
- Industry-leading gross margins of 72.4% demonstrating strong product pricing power and cost control
- Robust free cash flow generation of $28.8M (6% FCF margin) providing capital flexibility
- Strong liquidity position with 2.28x current ratio and $93.9M in cash equivalents
- Effective capital allocation driving 165% diluted EPS growth despite flat net income via share buybacks
NATR Investment Risks to Consider
- Critical margin compression with 67.2 percentage point gap between gross (72.4%) and operating (5.2%) margins indicating high SG&A or operational expenses
- Profitability stagnation with net income flat YoY despite 5.7% revenue growth, signaling inability to convert top-line growth to bottom-line earnings
- Modest organic growth of 5.7% YoY suggests limited market momentum and competitive pressure in saturated pharmaceutical preparations sector
Key Metrics to Watch
- Operating margin trend and SG&A expense ratio to assess operational efficiency improvement
- Revenue growth acceleration trajectory to validate market position sustainability
- Free cash flow conversion rate and capital allocation strategy (reinvestment vs. shareholder distribution)
NATR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.28x current ratio provides a solid financial cushion.
NATR Profitability Ratios
NATR vs Healthcare Sector
How NATURES SUNSHINE PRODUCTS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NATR Overvalued or Undervalued?
Based on fundamental analysis, NATURES SUNSHINE PRODUCTS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NATR Balance Sheet & Liquidity
NATR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NATURES SUNSHINE PRODUCTS INC's revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $0.40 reflects profitable operations.
NATR Growth Metrics (YoY)
NATR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $114.6M | $4.3M | $0.23 |
| Q2 2025 | $110.6M | $1.3M | $0.07 |
| Q1 2025 | $111.0M | $2.3M | $0.12 |
| Q3 2024 | $111.2M | $2.8M | $0.15 |
| Q2 2024 | $110.6M | $1.3M | $0.07 |
| Q1 2024 | $108.6M | $860.0K | $0.04 |
| Q3 2023 | $104.5M | $90.0K | $0.00 |
| Q2 2023 | $104.2M | $516.0K | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NATR Capital Allocation
NATR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NATURES SUNSHINE PRODUCTS INC (CIK: 0000275053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NATR
What is the AI rating for NATR?
NATURES SUNSHINE PRODUCTS INC (NATR) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NATR's key strengths?
Claude: Exceptional balance sheet strength with 0.01x debt-to-equity ratio and minimal long-term debt ($2.1M). Industry-leading gross margins of 72.4% demonstrating strong product pricing power and cost control.
What are the risks of investing in NATR?
Claude: Critical margin compression with 67.2 percentage point gap between gross (72.4%) and operating (5.2%) margins indicating high SG&A or operational expenses. Profitability stagnation with net income flat YoY despite 5.7% revenue growth, signaling inability to convert top-line growth to bottom-line earnings.
What is NATR's revenue and growth?
NATURES SUNSHINE PRODUCTS INC reported revenue of $480.1M.
Does NATR pay dividends?
NATURES SUNSHINE PRODUCTS INC does not currently pay dividends.
Where can I find NATR SEC filings?
Official SEC filings for NATURES SUNSHINE PRODUCTS INC (CIK: 0000275053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NATR's EPS?
NATURES SUNSHINE PRODUCTS INC has a diluted EPS of $1.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NATR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NATURES SUNSHINE PRODUCTS INC has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NATR stock overvalued or undervalued?
Valuation metrics for NATR: ROE of 12.1% (sector avg: 15%), net margin of 4.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NATR stock in 2026?
Our dual AI analysis gives NATURES SUNSHINE PRODUCTS INC a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NATR's free cash flow?
NATURES SUNSHINE PRODUCTS INC's operating cash flow is $35.3M, with capital expenditures of $6.5M. FCF margin is 6.0%.
How does NATR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.1% (avg: 12%), ROE 12.1% (avg: 15%), current ratio 2.28 (avg: 2).